Anti-verocytotoxin (VT)1, VT2 and VT2c antibodies in commercial intravenous immune globulins in Japan

Pediatrics International

Volumn 38, Issue 3, 1996, Pages 294-295

  Morooka, Tatsuya ^a   Umeda, Akiko ^b   Winkler, Monica ^c   Karmali, Mohamed A ^c   Amako, Kazunobu ^b   Oda, Teiichi ^d  

^a Fukuoka University Chikushi Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; SULFONATED IMMUNOGLOBULIN; TOXIN ANTIBODY; VEROTOXIN;

ANTIBODY TITER; ARTICLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOASSAY; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTIBODIES; BACTERIAL TOXINS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; JAPAN; SHIGA-LIKE TOXIN I; SHIGA-LIKE TOXIN II;

EID: 0030011234     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.1996.tb03492.x     Document Type: Article

References (9)

1. Karmali MA, Petric M., Lim C., Fleming PC, Arbus GS, Lior H. The association between hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 1985; 151: 775–82.
2. O’Brien AD, LaVeck GD. Purification and characterization of a Shigella dysenteriae I-like toxin produced by Escherichia coli. Infect. Immun. 1983; 40: 675–83.
3. Hii JH, Gyles G., Morooka T. et al. Development of verotoxin 2- and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1. J. Clin. Microbiol. 1991; 29: 2704–9.
4. Karmali MA, Petric M., Winkler M. et al. Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli verocytotoxin 1. J. Clin. Microbiol. 1994; 32: 1457–63.
5. Head S., Karmali MA, Roscoe ME, Petric M., Strockbine S., Wachsmuth K. Serological differences between verocytotoxin 2 and Shiga-like toxin II. Lancet 1988; ii: 751–3.
6. Ashkenazi S., Cleary MA, Lopez E., Pickering LK. Anticytotoxin-neutralizing antibodies in immune globulin preparations: Potential use in hemolytic-uremic syndrome. J. Pediatr. 1988; 113: 1008–14.
7. Milford DV, Taylor CM, Rose PE, Roy TCF, Rowe B. Immunologic therapy for hemolyticuremic syndrome. J. Pediatr. 1989; 115: 502–4.
8. Sheth KJ, Gill JC, Leichter HE. High-dose intravenous gamma-globulin infusion in hemolytic-uremic syndrome: A preliminary report. Am. J. Dis. Child. 1990; 144: 268–9.
9. Robson WLM, Fick GH, Jadavji T., Leung AKC. The use of intravenous gamma-globulin in the treatment of typical hemolytic uremic syndrome. Pediatr. Nephrol. 1991; 5: 289–92.